Compare Aurora Cannabis Inc (ACB) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Aurora Cannabis (ACB) trades at $5.15, down 1.72% on the day, amid a hostile takeover bid from Curaleaf. The stock shows a bullish technical trend with moving averages but overbought RSI levels. Fundamentally, 2025 revenue grew to $343.29M with a slim net profit of $1.59M, yet 2026 projections indicate a net loss of $120M. The company is debt-free with $138.48M cash, but profitability remains volatile.

The outlook is mixed: analyst consensus is a hold with a $5.92 price target, offering 15% upside, but risks include earnings inconsistency, competitive pressures, and the uncertain outcome of the takeover bid. Near-term performance hinges on international growth execution and resolving the Curaleaf offer.

Regeneron Pharmaceuticals (REGN) trades at $902.29, down 3.05% with strong fundamentals including 85.77% gross margins and consistent earnings beats. The stock shows bullish technical signals despite overbought RSI readings, supported by recent positive clinical trial data and a major $8 billion immunology alliance expansion with Sanofi. Revenue growth remains solid with 2025 revenue of $14.34 billion and net income of $4.50 billion.

Outlook remains positive with analyst consensus at Buy (69% of 49 analysts) and $887.79 price target. Key opportunities include pipeline expansion and immunology partnership, while risks involve competitive pressures in ophthalmology and clinical trial execution. The company maintains strong cash flow generation with $634.70M net cash flow in 2025.